Head-to-head · WeighScore
CoraDoc vs SnagRx
By GLP-1 ScorecardUpdated
Score comparison
CoraDoc has the higher recorded score — 76.8/100 to 57.9/100.
CoraDoc grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. CoraDoc advertises one upfront payment for a selected GLP-1 program. Its sales page and written refund policy give different answers about what you may get back.
Before you choose
Before comparing the headline prices, the CoraDoc review and the SnagRx review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.
If neither one fits, CoraDoc vs Trimi and CoreAge Rx vs SnagRx compare each of them with another graded program, and the list of alternatives to CoraDoc ranks the programs closest to CoraDoc on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | CoraDoc | SnagRx |
|---|---|---|
| WeighScore | 76.8/100 | 57.9/100 |
| Grade | C | C |
| Site position | #49 | #339 |
| Semaglutide | $924 upfront (12-month promotion, compounded) | $99/mo (one-month compounded plan) |
| Tirzepatide | $1,524 upfront (12-month promotion, compounded) | $149/mo (one-month compounded plan) |
| Coverage | Coverage not published | FAQ excludes Louisiana; confirm state eligibility |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
Strengths
- The 12-month promotion publishes the one-time payment for each medication
- The campaign lists clinician visits, medication, dose increases, shipping and supplies as included
- The weight-loss campaign advertises no automatic renewal for the annual offer
What to consider
- The lowest advertised monthly equivalents require paying for 12 months at once
- The refund policy describes a possible $100 clinical fee after medical ineligibility, despite the sales-page full-refund promise
- The pages checked did not name the dispensing pharmacy for an individual order
Site position #339 · C
Strengths
- One-month compounded injection plans advertised at $99 semaglutide / $149 tirzepatide
- Three-, six- and twelve-month prepaid options with published totals
- Terms name four possible pharmacy partners; individual assignment needs confirmation
- Product pages advertise evaluation, medication, coaching, messaging and shipping
What to consider
- Lowest $69/$119 monthly equivalents require $828/$1,428 twelve-month prepayments
- Final pharmacy-related charges may vary despite flat-dose marketing
- Refund policy makes payments final immediately; medical rejection refunds may deduct used services
- Cancellation cutoffs differ: five days before the prescription period ends versus 72 hours before billing
- Homepage state restrictions conflict with broader terms; confirm eligibility
Featured provider
SnagRx
SnagRx scores 57.9/100 (C). SnagRx lists one-month compounded injection plans at $99/$149, with prepaid discounts and refund rules to resolve before paying.
Commercial relationships affect this placement. The score comparison above is separate.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.